Pharmaceutical

AAIC 2024: Eisai presents positive long-term data with Leqembi

Patients treated with Leqembi over three years have demonstrated a slowing of Alzheimer’s disease progression.

Aug 3, 2024 - 04:00
AAIC 2024: Eisai presents positive long-term data with Leqembi
Patients treated with Leqembi over three years have demonstrated a slowing of Alzheimer’s disease progression.
Read the original article

Tags:

Previous Article

AbbVie acquires Cerevel Therapeutics for $8.7bn

Next Article

Agios Fails to Reach Primary Objective in Pediatric Study

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT+: AI therapy and ICU training: A first look at health apps for Apple Vision Pro

STAT+: AI therapy and ICU training: A first look at hea...

Feb 3, 2024

SK Bioscience gains UK authorisation for SKYCovion Covid-19 vaccine

SK Bioscience gains UK authorisation for SKYCovion Covi...

May 30, 2023

Health Canada approves Chiesi’s MYALEPTA for lipodystrophy

Health Canada approves Chiesi’s MYALEPTA for lipodystrophy

Feb 6, 2024